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ABSTRACT 
The standard of care for patients suffering cancer often includes treatment with nucleoside an-
alogues (NAs). NAs are internalized by cell-specific nucleobase/nucleoside transporters and, 
after enzymatic activation (often one or more phosphorylation steps), interfere with cellular 
nucleo(s)(t)ide metabolism and DNA/RNA synthesis. Therefore, their efficacy is highly de-
pendent on the expression and activity of nucleo(s)(t)ide-metabolizing enzymes, and altera-
tions thereof (e.g. by down/upregulated  expression or mutations) may change the susceptibil-
ity to NA-based therapy and/or confer drug resistance. Apart from host cell factors, several 
other variables including microbial presence may determine the metabolome (i.e. metabolite 
concentrations) of human tissues. Studying the diversity of microorganisms that are associat-
ed with the human body has already provided new insights in several diseases (e.g. diabetes 
and inflammatory bowel disease) and the metabolic exchange between tissues and their spe-
cific microbiota was found to affect the bioavailability and toxicity of certain anticancer 
drugs, including NAs. Several studies report a preferential colonization of tumor tissues with 
some mycoplasma species (mostly Mycoplasma hyorhinis). These prokaryotes are also a 
common source of cell culture contamination and alter the cytostatic activity of some NAs in 
vitro due to the expression of nucleoside-catabolizing enzymes. Mycoplasma infection may 
therefore bias experimental work with NAs, and their presence in the tumor microenviron-
ment could be of significance when optimizing nucleoside-based cancer treatment.  
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NUCLEOSIDE METABOLISM  
AND THERAPEUTIC  
ANTIMETABOLITES 
Biosynthesis of nucleo(s)(t)ides 
Pyrimidine and purine nucleotides are 
crucial in various cellular processes. They 
represent the building blocks for the syn-
thesis of nucleic acids (DNA and RNA), 
provide cellular energy [e.g. adenosine-5’-
triphosphate (ATP)], are involved as con-
jugates in biosynthetic processes (e.g. uri-
dine-5’-diphosphate-glucose), produce sig-
naling molecules (e.g. cyclic adenosine-5’-
monophosphate and cyclic guanosine-5’-
monophosphate) or act as enzyme co-
factors (e.g. nicotinamide adenine dinucle-
otide, flavin adenine dinucleotide, coen-
zyme A). The cellular requirements for nu-
cleotides can be met either by (i) de novo 
synthesis starting from low molecular 
weight precursors or (ii) the salvage path-
way, recycling nucleosides or nucleobases 
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from sources within the body or from food 
(Hatse et al., 1999).  
 
Pyrimidine nucleotide synthesis/ 
metabolism  
De novo synthesis of pyrimidine  
nucleotides 
As visualized in Figure 1, pyrimidine 
nucleotides can be assembled by the de no-
vo synthetic pathway from L-glutamine, L-
aspartic acid and 5-phosphoribosyl-1-pyro-
phosphate (PRPP) in a 6-step reaction pro-
cess resulting in uridine-5’-monophosphate 
(UMP) which is a precursor for other py-
rimidine nucleotides. Nucleotide kinase ac-
tivity converts UMP into uridine-5’-di-
phosphate (UDP) and uridine-5’-triphos-
phate (UTP). Amination of UTP by the 
rate-limiting CTP synthetase produces cyt-
idine-5’-triphosphate (CTP) and both CTP 
and UTP are incorporated into RNA. The 
formation of 2’-deoxyribonucleotides from 
UDP and cytidine-5’-diphosphate (CDP) is 
catalyzed by ribonucleotide reductase (RR) 
resulting in the production of 2’-deoxy-
uridine-5’-diphosphate (dUDP) and 2’-
deoxycytidine-5’-diphosphate (dCDP), re-
spectively (Hatse et al., 1999). Due to its 
relatively low enzymatic activity, RR-
catalyzed 2’-deoxyribonucleoside-5’-di-
phosphate (dNDP) synthesis is the rate-
limiting step in the entire process of DNA 
synthesis (Takeda and Weber, 1981; We-
ber, 1983). The de novo formation of thy-
mine (Thy) nucleotides solely occurs by 
methylation of 2’-deoxyuridine-5’-mono-
phosphate (dUMP) by thymidylate syn-
thase (TS) resulting in the formation of 
thymidine-5’-monophosphate (dTMP). In 
this reaction, 5,10-methylenetetrahydrofo-
late serves both as one-carbon donor and as 
reductant (Santi, 1980). Ultimately, after 
nucleotide kinase-mediated phosphoryla-
tion, the end products thymidine-5’-tri-
phosphate (dTTP) and 2’-deoxycytidine-
5’-triphosphate (dCTP) are substrates for 
DNA polymerization. 
Salvage of pyrimidines 
Various pyrimidine salvage enzymes 
metabolize pre-existing pyrimidine nucleo-
sides and nucleobases to meet the cellular 
nucleotide requirements. The salvage path-
way therefore provides an alternative to the 
de novo pathway. As visualized in Figure 
1, Thy and uracil (Ura) may be recycled in 
a reversible reaction catalyzed by thymi-
dine phosphorylase (TP) to generate thy-
midine (dThd) and 2’-deoxyuridine (dUrd), 
respectively (Friedkin and Roberts, 1954; 
el Kouni et al., 1993). Both dThd and dUrd 
are substrates for thymidine kinase (TK)-
mediated phosphorylation resulting in the 
formation of dTMP and dUMP, respective-
ly. Similarly, Ura may be a source of UMP 
after conversion into uridine (Urd) by uri-
dine phosphorylase (UP) and subsequent 
phosphorylation by uridine/cytidine (Urd/ 
Cyd) kinase (Weber, 1983). Alternatively, 
mostly in prokaryotes, uracil may also be 
metabolized directly into UMP by a uracil 
phosphoribosyltransferase (UPRT). How-
ever, even though a presumed UPRT gene 
has been reported in several tissues of the 
human body, no catalytically competent 
UPRT has been detected in mammals so 
far (Li et al., 2007). Cyd is phosphorylated 
by Urd/Cyd kinase to yield cytidine-5’-mo-
nophosphate (CMP).  Similarly, 2’-deoxy-
cytidine (dCyd) is metabolized by 2’-deo-
xycytidine kinase (dCK) to 2’-deoxycy-
tidine-5’-monophosphate (dCMP) which is 
a precursor of dUMP (upon deamination 
by the de novo enzyme CMP/dCMP-dea-
minase) and therefore of dTMP (Weber, 
1983). Cyd/dCyd deaminase converts Cyd 
and dCyd to Urd and dUrd, respectively. In 
contrast to some prokaryotes, mammalian 
cells do not encode a cytosine deaminase 
and therefore catabolism of cytosine deriv-
atives obligatorily occurs through deami-
nation at the nucleo(s)(t)ide level (Mullen 
et al., 1992). 
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Figure 1: Schematic representation of the salvage and the de novo biosynthesis of pyrimidine nucleo-
tides in mammalian cells. Dashed arrows represent enzyme activities that belong to the salvage path-
way (modified from Hatse et al., 1999). 
 
Purine nucleotide synthesis/metabolism  
In purine nucleotide synthesis, inosine-
5’-monophosphate (IMP) is the key nucle-
otide. IMP may be produced (i) by de novo 
synthesis, (ii) enzymatic conversion from 
AMP or GMP, or (iii) by salvage of hypo-
xanthine (Figure 2). 
De novo synthesis of purine nucleotides 
IMP is assembled from PRPP through 
10 successive reactions.  IMP may be con-
verted into either adenosine-5’-monophos-
phate (AMP) or guanosine-5’-monophos-
phate (GMP). The production of AMP 
from IMP, via the intermediate succinyl-
AMP, requires energy derived from guano-
sine-5’-triphosphate (GTP). Conversely the 
production of GMP from IMP requires en-
ergy from ATP (Lieberman, 1956; Weber 
et al., 1992). This allows the cell to control 
the proportions of AMP and GMP. For 
GMP formation, IMP is converted into 
xanthosine-5’-monophosphate (XMP), in a 
rate-limiting reaction catalyzed by IMP 
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dehydrogenase (IMPDH), and subsequent-
ly converted into GMP by GMP synthetase 
(Weber, 1983). IMP may again be pro-
duced from AMP by AMP deaminase in 
the purine nucleotide cycle (Tornheim and 
Lowenstein, 1972) or from GMP by GMP 
reductase. Nucleotide kinase activity pro-
duces adenosine-5’-diphosphate (ADP) 
and ATP from AMP; and guanosine-5’-
diphosphate (GDP) and GTP from GMP. 
The production of purine-based 2’-deoxy-
ribonucleotides is catalyzed by RR from 
ADP and GDP resulting in the formation of 
2’-deoxyadenosine-5’-diphosphate (dADP) 
and 2’-deoxyguanosine-5’-diphosphate 
(dGDP) which are further metabolized to 
produce 2’-deoxyadenosine-5’-triphos-
phate (dATP) and 2’-deoxyguanosine-5’-
triphosphate (dGTP). IMP therefore even-
tually provides ATP and GTP for RNA 
synthesis and also dATP and dGTP for 
DNA synthesis (Hatse et al., 1999). 
Salvage of purines 
IMP, AMP and GMP may also be pro-
duced by alternative routes controlled by 
purine salvage enzymes (Figure 2). Purine 
nucleosides [inosine (Ino) and guanosine 
(Guo)] are efficiently catabolized into their 
respective nucleobases [hypoxanthine (Hx) 
and guanine (Gua)] in a reversible reaction 
catalyzed by purine nucleoside phosphory-
lase (PNP). Whereas mammalian PNP 
does not catalyze the conversion of adeno-
sine (Ado) to adenine (Ade), prokaryotic 
PNP often also displays adenosine phos-
phorylase activity (Bzowska et al., 2000). 
Highly active phosphoribosyltransferases 
recycle nucleobases in the presence of 
PRPP directly to nucleotides. The conver-
sion of Ade to AMP is catalyzed by ade-
nine phosphoribosyl transferase (APRT) 
and Hx and Gua are efficiently metabo-
lized to IMP and GMP respectively, by 
hypoxanthine-guanine phosphoribosyl 
transferase (HGPRT) (Hatse et al., 1999).  
 
Nucleo(s)(t)ide metabolism in tumor cells 
The presence of several rate-limiting 
enzymes in the de novo anabolic pathways 
of pyrimidine and purine metabolism en-
sures a controlled proliferative capacity in 
normal cells. In tumor cells, elevated activ-
ities of such enzymes [e.g. CTP synthetase, 
RR, TS, IMPDH and DNA polymerase] 
have been reported (reviewed by Weber, 
1983; Hatse et al., 1999; Furuta et al., 
2010). In addition, the activity of anabolic 
salvage enzymes such as dCK, TK, APRT 
and HGPRT were found to be increased in 
tumor cells whereas decreased activities of 
catabolic enzymes [e.g. dihydropyrimidine 
dehydrogenase (DHPD)] were observed. 
These alterations can be attributed to (i) 
mutations preventing normal allosteric en-
zyme inhibition as demonstrated for dATP-
related inhibition of the R1 subunit of RR 
in murine lymphosarcoma cells (Weinberg 
et al., 1981), (ii) enzyme overexpression as 
observed for the R2 component of RR in 
premalignant breast lesions (Jensen et al., 
1994a), IMPDH in several tumor cell types 
(Collart et al., 1992; Hubermann et al., 
1994), or TS in metastatic melanoma 
(Vlaykova et al., 1997). Therefore, increa-
sed and imbalanced (2’-deoxy)nucleotide 
pools are often observed in tumor cells, 
leading to uncontrolled growth and increa-
sed mutation rates (de Korte et al., 1986; 
Meuth, 1989; Slingerland et al., 1994).  
 
Therapeutic pyrimidine- and purine-
based antimetabolites 
The treatment of cancer is largely 
based on inhibition of cellular replication 
by cytostatic drugs. These include alkylat-
ing agents, oncolytic antibiotics, topoiso-
merase inhibitors, antimetabolites and oth-
ers. In the early 1950s, the synthesis and 
cytostatic activity of purine nucleobase an-
alogues was reported for the first time. 
Several studies demonstrated inhibitory ac-
tivity of compounds such as 6-mercaptopu-
rine (6-MP; Figure 3), 6-thioguanine (6-
TG; Figure 3) and 2,6-diaminopurine 
against murine tumor cells in vitro and in 
vivo. Early clinical trials were performed 
and the administration of 6-MP to children 
with acute leukemia extended the median 
life expectancy of these patients to 12 
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Figure 2: Schematic representation of the salvage and the de novo biosynthesis of purine nucleotides 
in mammalian cells. Dashed arrows represent enzyme activities that belong to the salvage pathway 
(modified from Hatse et al., 1999). 
 
months compared with 3 - 4 months when 
treated with the antifolate methotrexate, 
being the mainstay treatment at that time. 
The FDA approval of 6-MP for the treat-
ment of acute pediatric leukemia in 1953 
was the start of extensive research on NAs 
as therapeutic agents (Elion, 1989). Cytar-
abine (cytosine-arabinofuranoside) was the 
first drug with a nucleoside-derived scaf-
fold that was approved by the FDA in 
1969. This drug is used in the treatment of 
acute myeloid leukemia (AML) and acute 
lymphoblastic leukemia (ALL) (Parker, 
2009). Originally, NAs found their applica-
tion in the treatment of hematological ma-
lignancies but currently a variety of pyrim-
idine and purine nucleoside derivatives al-
so show activity towards several solid tu-
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mors. With around 14 nucleobase/nu-
cleoside-based antineoplastic agents being 
approved by the FDA for the treatment of 
different malignancies, nucleoside ana-
logues (NAs) represent ~20 % of all clini-
cally approved anticancer drugs (Table 1).  
Three distinct classes of purine and py-
rimidine antimetabolites can be distin-
guished based on their chemical structure 
(Figure 3): (i) thiopurines, (ii) fluoropyrim-
idines and (iii) 2’-deoxyribonucleoside an-
alogues (Parker, 2009). The generalised 
mode of action of anticancer NAs is pre-
sented in Figure 4. Due to their similarity 
to the natural nucleic acid building blocks 
they are often internalized by cellular nu-
cleoside- or nucleobase-specific transporter 
proteins and activated (e.g. phosphory-
lated) by previously discussed anabolic 
salvage enzymes to their 5’-monophospha-
te derivatives (Galmarini et al., 2002). The 
initial reaction is often rate-limiting in the 
activation of NAs and is mainly catalyzed 
by phosphoribosyl transferases (APRT or 
HGPRT) for nucleobase analogues; or ki-
nases [e.g. dCK, TK and 2’-deoxyguanosi-
ne kinase (dGK)] for 2’-deoxyribonucleos-
de analogues (Elion, 1989; Johansson and 
Eriksson, 1996). Further phosphorylation 
to the 5’-diphosphate and 5’-triphosphate 
derivatives [catalyzed by nucleoside-5’-
monophosphate kinases (NMPK) and nu-
cleoside-5’-diphosphate kinases (NDPK), 
respectively] is required for most NAs to 
exert biological activity.  
 
Table 1: FDA -approved purine and pyrimidine antimetabolites  
(modified from Liekens et al., 2009; Parker, 2009) 
Drug Main uses FDA approval 
5-aza-2’-deoxycytidine (decitabine) Myelodysplastic syndromes 2006 
O6-methylarabinofuranosyl guanine 
(nelarabine) Acute lymphoblastic leukemia 2005 
2’-fluoro-2’-deoxyarabinofuranosyl-2-
chloroadenine (clofarabine) 
Relapsed or refractory pediatric acute 
lymphoblastic leukemia 2004 
5-aza-cytidine (vidaza) Myelodysplastic syndromes 2004 
N4-pentyloxycarbonyl-5’-deoxy-5-
fluorocytidine (capecitabine) 
Colorectal and metastatic breast  
cancer 1998 
2’,2’-difluoro-2’-deoxycytidine  
(gemcitabine) 
Pancreatic, non-small cell lung, breast 
and bladder cancer 1996 
2-chloro-2’-deoxyadenosine 
(cladribine) 
Hairy-cell leukemia, non-Hogkin  
lymphoma 1992 
arabinofuranosyl-2-fluoroadenine 
(fludarabine) Chronic lymphocytic leukemia 1991 
2’-deoxycoformycin (pentostatin) Hairy-cell leukemia 1991 
5-fluoro-2’-deoxyuridine (floxuridine) Metastatic colorectal cancer 1970 
arabinofuranosylcytosine (cytarabine) Acute lymphoblastic and myeloid  leukemia 1969 
6-thioguanine Acute lymphoblastic and myeloid  leukemia 1966 
5-fluorouracil Gastrointestinal, pancreatic, head and neck, renal, skin and breast cancers 1962 
6-mercaptopurine Acute lymphoblastic leukemia 1953 
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Thiopurines 
                                                                                                        
 
                           6-mercaptopurine (6-MP)                                                        6-thioguanine (6-TG) 
 
Fluoropyrimidines 
 
                                                         
                   
        5-fluorouracil (5-FU)                                   capecitabine                                            floxuridine   
                                        
2’-deoxynucleoside analogues 
                                                                          
     gemcitabine (dFdC)                                  cladribine (2-CdA)                                 fludarabine (F-ara-A) 
 
Figure 3: Chemical structures of representative NAs belonging to different classes of nucleobase/ 
nucleoside analogues 
 
 
 
Figure 4: Schematic representation of the up-
take, activation and mode of action of nucleo-
base/nucleoside analogues (modified from 
Galmarini et al., 2002).  
 
Activated NAs may (i) inhibit one or 
several crucial enzymes in the de novo or 
salvage nucleo(s)(t)ide metabolism or (ii) 
incorporate in nucleic acids. Both actions 
may lead to lethal DNA/RNA damage or 
inhibition of their synthesis, ultimately re-
sulting in induction of apoptosis.  
Enzymes responsible for the catabo-
lism of pyrimidines and purines [e.g. 
DHPD and xanthine oxidase (XO), respec-
tively] are often implicated in the detoxifi-
cation of NAs (Galmarini et al., 2002). 
Most cells in adults are quiescent and 
therefore not actively proliferating. Target-
ing DNA synthesis may thus result in a 
certain level of selectivity towards tumor 
cells, although co-lateral toxicity mostly 
occurs in host tissues containing cells in 
their replicative state such as bone marrow, 
hair follicles, intestinal mucosa, etc. (Par-
ker, 2009). The design of novel anticancer 
NAs focuses on drugs with a different 
mode of action or target or improved bioa-
vailability/solubility. Several compounds 
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are currently under (pre)clinical investiga-
tion (reviewed by Jordheim et al., 2013). 
 
Suicide gene therapy of cancer using 
non-mammalian enzymes  
The eventual therapeutic efficiency of 
NAs is very much dependent on the ex-
pression and activity of nucleo(s)(t)ide-
metabolizing enzymes and their relative 
balances (activity rates) in tumor cells. 
Since non-mammalian enzymes (e.g. viral, 
prokaryotic and insect) are often endowed 
with a different substrate specificity or ac-
tivity compared with their mammalian 
counterparts, the expression of such en-
zymes in tumor cells may alter NA-based 
treatment efficiency. In this respect, the se-
lective introduction of non-mammalian 
genes in tumor cells to activate NA pro-
drugs has been investigated as a treatment 
modality for cancer. Such approaches are 
referred to as suicide gene therapy and the 
different gene/NA systems have been re-
viewed recently (Ardiani et al., 2012; Du-
arte et al., 2012). The therapeutic use of su-
icide gene therapy remains limited due to 
(i) inefficient gene delivery, (ii) poor cata-
lytic conversion of nucleo(s)(t)ide pro-
drugs by wild-type enzymes, (iii) toxicity 
caused by commensal prokaryotes in heal-
thy tissues (e.g. intestinal) or (iv) thermo-
lability of non-mammalian proteins at 
physiological temperature. In order to in-
crease chemotherapeutic selectivity at the 
tumor site and to lower the required dose 
of prodrugs, research has focused on engi-
neering more efficient mutant enzymes that 
differ in substrate specificity from both 
human and wild-type prokaryotic enzymes. 
Three illustrative gene therapy systems 
will be described. 
Herpes simplex virus thymidine kinase 
(HSV-TK) phosphorylates the guanosine 
analogue ganciclovir (GCV) > 1000-fold 
more efficiently than cytosolic TK. There-
fore, a selective phosphorylation of GCV 
to its 5’-monophosphate derivative (GCV-
MP) may be obtained in HSV-TK-
expressing tumor cells. GCV-MP is subse-
quently phosphorylated by endogeous en-
zymes (i.e. GMP kinase and NDPK) to 
produce GCV-5’-triphosphate which caus-
es cell death after incorporation into the 
DNA. Succesful results have been obtained 
with the HSV-TK/GCV system in several 
pre-clinical and some clinical studies. 
However its use remains limited due to the 
high doses of GCV that are required for 
therapeutic efficiency. 
In contrast to mammalian cells, bacte-
ria and yeast express a functional cytosine 
deaminase (CD) that catalyzes the hydro-
lytic deamination of the non-toxic prodrug 
5-fluorocytosine (5-FC) to produce 5-
fluorouracil (5-FU; Figure 3). 5-FU repre-
sents the mainstay of treatment for differ-
ent malignancies. A CD/5-FC suicide gene 
therapy system has been explored using the 
Escherichia coli or Saccharomyces cere-
visiae CD gene. Apart from selective acti-
vation of the drug at the tumor site, such 
system may be beneficial for some patients 
since 5-FC (and not 5-FU) may efficiently 
cross the blood-brain barrier (Vermes et 
al., 2000). Also, in contrast to the HSV-
TK/GCV system, 5-FU (a small uncharged 
molecule) is not dependent on the occur-
rence of cell-to-cell contact or gap junc-
tions to affect adjacent tumor cells (by-
stander effect) since the drug can pass the 
cell membrane by non-facilitated diffusion 
(Greco and Dachs, 2001). 
Fludarabine (F-ara-A; Figure 3) and 
other adenosine analogues [e.g. 6-methyl-
purine-2’-deoxyriboside (6-MeP-dR) and 
2-fluoro-2’-deoxyadenosine] have been 
studied extensively for their use against 
tumor cells, expressing E. coli PNP (re-
viewed in Zhang et al., 2005). Whereas 
mammalian PNP generally does not cata-
lyze the phosphorolysis of (d)Ado and its 
analogues, prokaryotic PNP efficiently 
converts F-ara-A into its highly cytostatic 
base 2-fluoroadenine (2-FAde). 2-FAde 
may also diffuse to neighbouring tumor 
cells and inhibit RNA and/or protein syn-
thesis when metabolized to 2-fluoro-ATP 
(by APRT-catalyzed ribophosphorylation 
and subsequent nucleotide kinase activity) 
(Hong et al., 2004).  
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Prokaryotic enzymes expressed at the 
tumor site due to a natural bacterial infec-
tion could also affect NA-based therapy. 
As will be discussed in detail below, bacte-
ria belonging to the Mycoplasmataceae are 
a common source of mammalian cell cul-
ture contaminations and are reported to se-
lectively colonize tumor tissue in cancer 
patients. This phenomenon is still greatly 
unrecognized and potentially underesti-
mated but may have important implications 
in the optimization of current anticancer 
chemotherapy. 
 
MYCOPLASMAS 
General characteristics 
In 1898 the contagious bovine pleuro-
pneumonia (CBPP) agent, an important 
cause of lung disease in ruminants, was the 
first mycoplasma to be isolated and culti-
vated (Nocard and Roux, 1898). The term 
mycoplasma refers to its mycelar fungus-
like morphology and CBPP was later iden-
tified as Mycoplasma mycoides subsp. my-
coides small colony type (ter Laak, 1992). 
Indicative for its socioeconomic impact is 
the fact that CBPP is the only bacterial dis-
ease to be included in the A-list of the 
World Organization for Animal Health of 
prioritized communicable animal diseases 
(http://www.oie.int).  
Bacteria from the genera Mycoplasma, 
Ureaplasma and Allobaculum belong to 
the family Mycoplasmataceae (trivial 
name: mycoplasmas) in the class of the 
Mollicutes [mollis, soft; cutis, skin (Latin)] 
which encompasses prokaryotes character-
ized by the lack of a rigid cell wall. Cur-
rently, at least 204 mycoplasmas are de-
scribed of which 119 are classified under 
the genus Mycoplasma (Garrity et al., 
2007). Mycoplasmas are the smallest (both 
in cellular dimensions and genome) and 
simplest self-replicating organisms. A va-
riety of morphological entities were report-
ed for mycoplasmas, with the predominant 
shape being a sphere with a diameter rang-
ing from 0.3 - 0.8 µm. They are considered 
to have evolved from Gram-positive bacte-
ria by degenerative evolution, including a 
strong genome reduction and the loss of a 
rigid cell wall. These prokaryotes are sur-
rounded by a plasma membrane only and 
therefore proved to be a valuable tool in 
membrane studies (Razin and Hayflick, 
2010). Due to their small double stranded 
DNA genome (smallest ≈ 580 kb), their 
metabolic activity is limited and mainly 
focused on energy generation. Mycoplas-
mas lack the genes for several biosynthetic 
metabolic pathways (e.g. the oxidative 
phosphorylation pathway and the tricar-
boxylic acid cycle) and have been studied 
extensively to define the minimal set of 
genes required for living organisms (the 
so-called minimal cell concept) (Razin et 
al., 1998; Glass et al., 2006). 
 
Nucleo(s)(t)ide metabolism in  
mycoplasmas 
The economization of genes in mol-
licutes is also reflected in their pyrimidine 
and purine metabolism and several inter-
species variations in the biochemical path-
ways of mycoplasmas have been observed 
using enzymatic assays and comparative 
genomics (Bizarro and Schuck, 2007). 
Most mycoplasma species however share 
the inability to synthesize purine and py-
rimidine nucleotides de novo (Mitchell and 
Finch, 1977; Pollack et al., 1997). Display-
ing a parasitic lifestyle, mycoplasmas 
therefore scavenge preformed nucleic acid 
precursors from their host tissue which are 
efficiently internalized and recycled using 
several transport mechanisms and salvage 
enzymes, respectively.  
De novo biosynthesis of pyrimidine and 
purine nucleotides in mycoplasmas 
As reviewed by Finch and Mitchell 
(1992), nutritional studies on the develop-
ment of minimal growth media indicate a 
lack of de novo synthesis of pyrimidine 
and purine nucleotides in most mollicutes. 
The addition of yeast extract to culture 
media was shown to promote mycoplasma 
growth in vitro. This was partly attributed 
to its high content of nucleic acids (precur-
sors). Later, it was shown that mycoplasma 
growth was also supported by a balanced 
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supply of DNA and RNA or by the addi-
tion of oligonucleotides. Further research 
revealed that the DNA synthesis require-
ments of mollicutes could also be met by 
the addition of dThd alone. Nucleic acid 
biosynthesis was studied extensively in M. 
mycoides subsp. mycoides for which a min-
imal growth medium was defined. Its sim-
plest requirements for nucleic acid precur-
sors were found to be Gua, Ura and Thy, 
which may be metabolized by a series of 
anabolic salvage enzymes. Using radio-
labeled precursor studies, the absence of de 
novo synthesis was confirmed in most my-
coplasma species (Mitchell and Finch, 
1977; McElwain et al., 1988), Mycoplasma 
penetrans being a possible exception as in-
dicated in a study by Sasaki and colleagues 
(2002). While other mycoplasmas lack ei-
ther the gene encoding Urd/Cyd kinase or 
the gene encoding 5’-nucleotidase (in-
volved in the salvage of UMP), both genes 
were found to be absent in M. penetrans. 
However, using comparative genomics, a 
set of 6 genes were indentified in the ge-
nome of M. penetrans, encoding enzymes 
involved in an orotate-related pathway for 
the conversion of carbamoyl-phosphate to 
UMP. Since carbamoyl-phosphate is pro-
duced in the ATP-generating arginine di-
hydrolase pathway, this suggests that in M. 
penetrans UMP may be formed not only 
from Ura (by UPRT activity) but also us-
ing the de novo pathway. 
It has long been assumed that most 
mollicutes lack a functional TS and there-
fore are unable to catalyze the methylation 
of dUMP to dTMP. As will be discussed 
later, dTMP was supposedly generated by 
salvage of Thy or dThd or by the uptake of 
dTMP from the environment (Pollack et al, 
1997).  However, TS activity has been de-
scribed for Mycoplasma pneumoniae 
(Wang et al., 2010) and a flavin-dependent 
TS, without sequence homology to previ-
ously identified TS-encoding genes, was 
identified in M. mycoides and Ureaplasma 
parvum, the latter being a human pathogen 
colonizing the urogenital tract (Wehelie et 
al., 2010). 
Salvage of pyrimidines and purines in my-
coplasmas 
Unlike the genome of their mammalian 
host (average human GC-content ~ 46 %), 
mycoplasma genomes are characterized by 
a high AT-content (70 - 75 %). In order to 
produce the required intracellular dTTP 
and dATP concentrations starting from the 
precursors supplied by their host, rear-
rangements of the internalized nucleobas-
es/nucleo(s)(t)ides are required (Wang et 
al., 2001). Various mycoplasma-encoded 
catabolic and anabolic nucleotide salvage 
enzymes [e.g. nucleoside phosphorylases 
(NPs), nucleoside deaminases, nucleoside 
kinases, phosphoribosyltransferases, etc.] 
have been identified (Tham et al., 1993; 
Himmelreich et al., 1996) and mycoplasma 
infection was reported to upregulate host 
cell nucleoside catabolism and downregu-
late nucleoside anabolism in vitro (John-
son, 2008; Merkenschlager et al., 1988). 
Despite several inter-species variations, a 
general purine and pyrimidine salvage 
pathway for mycoplasmas has been out-
lined (Figure 5) (Finch and Mitchell, 1992; 
Pollack et al., 1997; Bizarro and Schuck, 
2007).  
As shown by Mitchell and Finch 
(1977) NP activity rapidly breaks down 
pyrimidine and purine nucleosides when 
supplied to mycoplasma cultures. As a re-
sult, (2’-deoxy)ribose-1-phosphate and the 
corresponding nucleobases are produced. 
High NP activity in mycoplasma-
contaminated cell cultures has led to the 
design of assays to detect a mycoplasma 
infection in vitro. These assays are based 
on (i) decreased dTTP incorporation in in-
fected host cells due to the presence of 
mycoplasma-encoded TP or (ii) Ado ca-
tabolism due to mycoplasma-encoded Ado 
phosphorylase (McGarrity and Carson, 
1982; Jakway and Shevach, 1984; Si-
nigaglia and Talmadge, 1985; Merken-
schlager et al., 1988).  
Depending on the cellular require-
ments, nucleobases may be converted di-
rectly to their nucleoside-5’-monophospha-
te (NMP) derivatives by appropriate phos- 
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Figure 5: Schematic representation of potential pathways for nucleobase/nucleoside salvage in my-
coplasmas (modified from Wang et al., 2001)  
Enzymes: (1) ATP- or PPi-dependent nucleoside kinases; (2) nucleoside phosphorylases; (3) phos-
phoribosyl transferases; (4) nucleoside phosphotransferases; (5) ribonucleotide reductase 
Abbreviations: (d)N, (2’-deoxy)-nucleoside; (d)NMP, (2’-deoxy)nucleoside-5’-monophosphate; (d)NDP, 
(2’-deoxy)nucleoside-5’-diphosphate; (d)NTP, (2’-deoxy)nucleoside-5’-triphosphate; PRPP, 5-phos-
phoribosyl-1-pyrophosphate; 5’-NT, 5’-nucleotidase; NMPK, nucleoside monophosphate kinase 
 
phoribosyl transferases (UPRT, APRT or 
HGPRT). Alternatively, (2’-deoxy)NMP 
[(d)NMP] may be produced from internal-
ized (2’-deoxy)nucleosides by ATP-
dependent or pyrophosphate(PPi)-depen-
dent nucleoside kinases (NKs). The pres-
ence of PPi-dependent NKs is presumably 
valuable in reconstituting the required (2’-
deoxy)nucleotides without consuming ATP 
(Tryon and Pollack, 1984; Wang et al., 
2001). Some mycoplasmas may also re-
plenish their deoxynucleotide pools by nu-
cleoside phosphotransferase activity, trans-
ferring the 5’-phosphate moiety from a 
preformed NMP to 2’-deoxyribonucleo-
sides (Wang et al., 2001). Also, while in 
most prokaryotic cells nucleotides are de-
phosphorylated by periplasmatic phospha-
tases prior to uptake, mycoplasmas were 
shown to possess a single transporter sys-
tem mediating the uptake of (d)NMPs. Ex-
ogenous supply of dTMP may therefore 
substitute for Thy when culturing myco-
plasmas (Neale et al., 1984; Finch and 
Mitchell, 1992).  
(d)NMPs are metabolized by sequential 
phosphorylation catalyzed by NMPK and 
NDPK. However, a gene encoding NDPK 
has not yet been identified in the genome 
of mycoplasmas and it has been hypothe-
sized that NDPK activity in mycoplasmas 
may be attributed to glycolytic kinases 
(such as pyruvate kinase) (Pollack et al., 
2002), NMPK (Wang, 2007), or adenylate 
kinase (Bizarro and Schuck, 2007).  
RR-catalyzed reduction of ribonucleo-
tides to 2’-deoxyribonucleotides in myco-
plasmas is believed to occur not only at the 
nucleoside-5’-diphosphate (NDP) level, as 
is observed in most organisms, but possi-
bly NTPs are also directly reduced to gen-
erate dNTPs (Pollack, 2001). Since some 
mycoplasmas appear not to express a func-
tional RR, these organisms may be fully 
dependent on deoxyribonucleoside salvage 
to meet their dNTP requirements (Glass et 
al., 2000). 
 
Pathogenicity 
Mycoplasmas are common parasites of 
mammals, plants, reptiles, arthropods and 
fish and were originally considered to be 
surface adherent (Figure 6). However, it is 
now generally accepted that several species 
(e.g. M. pneumoniae, M. penetrans and 
Mycoplasma fermentans, M. genitalium 
and Mycoplasma hyorhinis) may be inter-
nalized by the host cells, possibly shielding 
them from the host immune system and an-
tibiotic treatment (Jensen et al., 1994b; 
? 
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Figure 6: Scanning Electron Micrograph of Mycoplasma sp. on the surface of a fibroblast (© Dr. Phil-
lips/Visuals Unlimited/Corbis) 
 
Kornspan et al., 2010; Razin and Hayflick, 
2010; Rottem et al., 2012). Due to their 
limited biosynthetic capabilities, myco-
plasmas often exhibit a fairly strict host 
and tissue specificity. 
In the human body, mollicutes mostly 
reside as commensals of the mucosal sur-
faces of the urogenital and respiratory 
tracts, often causing chronic asymptomatic 
infections (Razin et al., 1998). Transmis-
sion occurs by aerosol exposure or direct 
(intimate) contact between mucosal surfac-
es. Of healthy individuals studied, 84 % 
were determined to be a carrier of Myco-
plasma salivarium or Mycoplasma orale in 
the oropharynx, and Mycoplasma hominis, 
M. fermentans and Ureaplasma urealyti-
cum  are frequently isolated from the uro-
genital tract (Krause and Taylor-Robinson, 
1992). These data indicate that several my-
coplasmas may be considered as being part 
of the resident flora of the human body. 
However, some species are also clearly as-
sociated with disease and the development 
of pathology may then depend on the spe-
cific site(s) of colonization, amount pre-
sent, strain characteristics or lack of muco-
sal immunity (Krause and Taylor-Robin-
son, 1992).  U. urealyticum is part of the 
genital flora of 45 - 75 % of the sexually 
active human population and infection is 
linked to the development of non-gono-
coccal urethritis (Murray et al., 2002).  The 
most profoundly studied human myco-
plasma is M. pneumoniae, which was iden-
tified as the etiological agent of primary 
atypical pneumonia (Waites and Talking-
ton, 2004). Using a special attachment or-
ganelle, this pathogen attaches to the sur-
face of ciliary tracheal epithelia and he-
molyses red blood cells by producing hy-
drogen peroxide. Furthermore, direct inva-
sion of M. pneumoniae to extrapulmonary 
sites and/or induction of autoimmune re-
sponse may result in severe, possibly life-
threatening, complications. Due to their 
lack of a cell wall, mycoplasmas are re-
sistant to treatment by cell wall-targeting 
antibiotics such as β-lactams (e.g. penicil-
lin) but infections can be managed by the 
administration of macrolides, tetracyclines 
or fluoroquinolones  (Waites and Talking-
ton, 2004). 
Additionally, several studies have in-
vestigated the link of mycoplasmas with a 
variety of diseases of unclear etiology (e.g. 
the Gulf War syndrome, chronic fatigue 
syndrome, Crohn’s disease and others) 
(Baseman and Tully, 1997). However the 
specific association of mycoplasmas with 
these pathologies is doubtful (Razin, 
1998). Also, a possible role for mycoplas-
mas as a co-factor of human immunodefi-
ciency virus (HIV) infection and pathogen-
esis was studied extensively. M. fer-
mentans and M. penetrans were frequently 
observed intracellularly in a variety of 
nonphagocytic cells in AIDS (acquired 
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immunodeficiency syndrome) patients but 
the relevance of AIDS-associated myco-
plasmas remains unclear (Blanchard and 
Montagnier, 1994; Razin and Hayflick, 
2010). 
 
Mycoplasmas as cell culture  
contaminants 
Studies have revealed that 15 - 80 % of 
the mammalian cell cultures worldwide are 
infected with mycoplasmas. Such contami-
nations may remain undetected for a long 
period of time as they do not produce the 
turbid growth that is characteristically ob-
served in case of other bacterial or fungal 
infections in cell cultures (Drexler and Up-
hoff, 2002; Rottem et al., 2012). The main 
sources of contamination were identified as 
animal serum, trypsin, aerosols from pre-
viously infected cell cultures and laborato-
ry staff (Drexler and Uphoff, 2002). Over 
90 % of the contaminations were attributed 
to the human species M. orale and M. fer-
mentans (presumably originating from la-
boratory manipulations); the bovine spe-
cies Mycoplasma arginini (frequently iso-
lated from bovine serum); and the swine 
pathogen M. hyorhinis (possibly trans-
ferred by trypsin which is/was obtained 
from swine pancreas) (Rottem and Barile, 
1993; Razin and Hayflick, 2010). All cell 
types may be subject to mycoplasma con-
tamination, however continuously propa-
gated cell lines are more frequently infect-
ed compared with primary cell lines or 
those subcultivated for a limited time peri-
od. Contamination of primary cell lines is 
mostly due to an infection already present 
in the tissue from which the cell culture 
originated. Especially the foreskin, female 
urogenital tract and tumor tissues often 
show a high mycoplasma infection rate 
(Rottem et al., 2012).  
Mycoplasmas adhere to their host cells 
via a process mediated by adhesins, acces-
sory proteins and host receptors (reviewed 
by Rottem, 2003). Some mycoplasmas 
(e.g. M. fermentans) may fuse with their 
host cells when direct contact of the myco-
plasma membrane with the cytoplasmic 
membrane of the eukaryotic cell has been 
established. Mycoplasmal components 
(e.g. nucleases) may then be introduced in-
to the host cell. Depending on the infected 
cell type and mycoplasma species or strain 
characteristics, host cells may display nu-
trient deprivation (e.g. amino acids and nu-
cleic acid precursors), cytopathic effects 
and/or adherence or fusion-related damage. 
Also, several mycoplasmas (e.g. M. pene-
trans) may be internalized and remain via-
ble within host cells. Intracellular multipli-
cation of these invasive mycoplasma spe-
cies has also been hypothesized (Rottem, 
2003; Rottem et al., 2012). 
Several methods for the detection and 
eradication of a mycoplasma infection in 
cell cultures have been described. Detec-
tion procedures include immunohistochem-
istry, electron microscopy, isolation and 
subsequent culturing assays, polymerase 
chain reaction (PCR) and various less spe-
cific assays. Elimination of the mycoplas-
mas may be achieved by physical (e.g. fil-
tration), chemical (e.g. detergent expo-
sure), immunological (e.g. in vivo passage 
through mice) and chemotherapeutic (e.g. 
antibiotics) eradication procedures. How-
ever, many of these assays have proven un-
reliable and/or time consuming and antibi-
otic treatment is by far the most common 
and efficient approach to remove myco-
plasmas from the infected cell cultures 
(Drexler and Uphoff, 2002).  
 
Mycoplasmas and cancer 
According to the American Cancer So-
ciety, 15 - 20 % of all cancers worldwide 
are caused by infectious agents. The can-
cer-inducing mechanisms of several on-
coviruses (e.g. human papillomavirus) are 
well documented and the link between 
specific bacterial infections (e.g. Helico-
bacter pylori) and the development of ma-
lignancy (e.g. gastric cancer) is generally 
accepted (zur Hausen, 2009; Touati, 2010). 
Also other prokaryotes (e.g. Streptococcus 
sp., Salmonella thyphii, Chlamydia sp. and 
Mycoplasma sp.) are suggested to exhibit 
tumorigenic properties or may associate 
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with tumor tissue in cancer patients as op-
portunistic pathogens (reviewed by Vo-
gelmann and Amieva, 2007; Cummins and 
Tangney, 2013). However, the oncogenic 
potential of mycoplasmas and their role in 
cancer development remains unclear.  
Mycoplasmas and oncogenesis 
In vitro studies have shown that pro-
longed exposure of cell cultures to differ-
ent mycoplasmas (e.g. M. fermentans, M. 
penetrans, M. genitalium, M. arginini and 
M. hyorhinis) may induce chromosomal 
instability and malignant transformations, 
thereby promoting immortalization and 
characteristic tumor cell properties (i.e. in-
creased migration, invasion and in vivo 
tumor formation) (Tsai et al., 1995; Zhang 
et al., 2004; 2006a; Namiki et al., 2009). 
The oncogenic potential of mycoplasmas 
may be due to a multistage process involv-
ing overexpression of oncogenes (e.g. H-
ras and c-myc) (Zhang et al.,1997; 2006b), 
the increase of growth factor production 
(e.g. bone morphogenetic protein 2) (Jiang, 
et al., 2008), reduced activation of tumor 
suppressors (e.g. p53), and prevention of 
apoptosis (Feng et al., 1999; Logunov et 
al., 2008). 
Extensive research has been done on 
p37, a M. hyorhinis-encoded surface pro-
tein, which is presumably part of a high-
affinity transport system. Antibodies to-
wards p37 were detected in the serum of 
cancer patients and isolation of the protein 
revealed that it originated from mycoplas-
mas (Fareed et al., 1988; Ketcham et al., 
2005) The protein was also detected on the 
surface of FS9 mouse sarcoma cells and 
found to be responsible for their highly in-
vasive behavior, which could be trans-
ferred to other cell lines by the addition of 
cell free FS9 supernatant. Mycoplasma 
contamination in these cell cultures was 
confirmed and elimination of the myco-
plasmas or the addition of a specific anti-
p37 antibody reduced invasiveness of the 
cells (Dudler et al., 1988; Schmidhauser et 
al., 1990). Subsequent in vitro studies have 
shown that p37 inhibits the adhesion and 
enhances motility, migration and invasion 
of gastric and prostatic tumor cells 
(Ketcham et al., 2005; Liu et al., 2006). 
The expression of p37 in tumor cells was 
found to promote lung metastasis in vivo 
which was attributed to activation of ma-
trix metalloproteinase-2 thereby inducing 
epidermal growth factor recepter (EGFR) 
(Gong et al., 2008). A protein with homol-
ogy to p37 (Ag 243-5), was identified in 
M. arginini and was also shown to promote 
metastasis in vivo (Ushio et al., 1995). 
Therefore, it is hypothesized that myco-
plasmas may stimulate tumor cell invasion 
and contribute to metastasis. 
Association of mycoplasmas with estab-
lished tumor tissue 
Since the mid-1990s, the association 
between mycoplasmas and tumor tissue in 
cancer patients has been documented. Us-
ing different DNA-based or immunological 
detection assays, a high mycoplasma infec-
tion ratio was reported in several types of 
tumors (Table 2). 
The first study reporting a high preva-
lence of mycoplasmas in tumor tissue was 
published by Sasaki et al. (1995), who 
found 48 % of gastric adenocarcinoma 
samples to be infected with Mycoplasma 
sp. (M. hyorhinis in 8 out of 11 positive 
samples). Yang et al. (2010) showed the 
presence of M. hyorhinis and M. fer-
mentans in respectively 64 % and 31 % of 
resected gastric cancer tissues. Moreover, a 
higher mycoplasma infection ratio was ob-
served in stage 3 - 4 samples compared 
with stage 1 - 2 samples and in diffuse-
type compared with intestinal-type gastric 
carcinoma. Interestingly, lymph node me-
tastasis was more evident in patients with 
mycoplasma-positive tumors (Yang et al., 
2010). Mycoplasma sp. infections were al-
so detected in 59 % and 21 % of ovarian 
cancer and cervical condyloma tissues, re-
spectively (Chan et al., 1996; Kidder et al., 
1998). However these studies did not in-
clude non-malignant control samples and 
therefore do not provide information on the 
preferential colonization of tumor tissue by 
mycoplasmas. 
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Table 2: Prevalence of mycoplasmas in tissue samples from cancer patients (cancerous, pre-cancerous or non-cancerous tissue) and from a control group 
(diseased or normal tissue) 
Cancer type
Tissue from cancer patients Tissue from control group 
Species Assay method Reference Cancerous Pre-cancerous 
Non-
cancerous Diseased Normal 
Gastric  
48 % (n = 23) - - - - M. hyorhinis PCR Sasaki et al., 1995 
56 % (n = 90) - - 28 – 37 % (n=142) - M. hyorhinis IHC Huang et al., 2001 
63.9 % (n = 61) - - - - M. hyorhinis nested PCR Yang et al., 2010 
31.1 % (n = 61) - - - - M. fermen-tans nested PCR Yang et al., 2010 
Ovarian 59.3 % (n= 27) - - - - unidentified PCR/ELISA Chan et al., 1996 
Cervical  21.4 % (n = 14) - - - - unidentified PCR/ELISA Kidder et al., 1998 
Esophageal 50.9 % (n = 53) - - - - M. hyorhinis IHC Huang et al., 2001 
Lung 
22.2 % (n = 27) - - - 5 % (n = 40) unidentified PCR Pehlivan et al., 2004 
52.6 % (n = 59) - - - - M. hyorhinis IHC Huang et al., 2001 
100 % (n = 32) - - - - unidentified RT-PCR Apostoulou et al., 2011 
Breast 39.7 % (n = 63) - - - - M. hyorhinis IHC Huang et al., 2001 
Glioma 41 % (n = 91) - - - - M. hyorhinis IHC Huang et al., 2001 
Colon 55.1 % (n = 58) - - 20.9 % (n = 49) - M. hyorhinis IHC Huang et al., 2001 
Prostate 
22.4 % (n = 58) 13 % (n = 23) - 6.8 % (n = 44) 0 % (n = 27) M. hominis PCR Barykova et al., 2011 
54.8 % (n = 31) 53 % (n = 32) - 20 % (n = 60) 0 % (n = 27) M. hominis qPCR Barykova et al., 2011 
35 % (n = 31) - 12.9 % (n = 31) 0 % (n = 31) - unidentified PCR Erturhan et al., 2013 
RCC 82 % (n = 33) 67 % (n = 33) 36 % (n= 33) - 15 % (n = 35) unidentified Nested PCR Pehlivan et al., 2005 
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Huang et al. (2001) performed a large 
screening of different cancer tissues using 
immunohistochemistry and reported M. hy-
orhinis infection rates of 40 - 53 % in 
esophageal, lung, breast cancer and glioma 
tissue samples. Importantly, increased my-
coplasma infection ratios were detected in 
gastric carcinoma (56 %) compared with 
other gastric diseases (28 - 37 %, depending 
on the pathology), and colon carcinoma 
(55 %) compared with tissue derived from 
adenomatous polyps (21 %). Surprisingly, 
both for the gastric and colon carcinomas, 
the authors found M. hyorhinis infection 
significantly increased in highly differenti-
ated compared with poorly differentiated 
tissues whereas most studies report an in-
creased mycoplasma infection in high ver-
sus low grade samples. 
Mycoplasma infection was also com-
pared in prostate biopsies from healthy in-
dividuals and patients with elevated pros-
tate specific antigen (PSA) levels, indica-
tive of benign prostatic hyperplasia (BPH), 
high-grade prostatic intraepithelial neoplasy 
(HGPIN; precursor for prostate cancer) and 
prostate cancer (Barykova et al., 2011). No 
mycoplasmas could be detected in the con-
trol group using PCR, whereas the presence 
of U. urealyticum (1 %), M. genitalium 
(6 %) and M. hominis (15 %) was demon-
strated in samples derived from patients 
with elevated PSA levels. Moreover, M. 
hominis infection correlated with the severi-
ty of the diagnosis (7 %, 13 % and 22 % for 
BPH, HGPIN and cancerous tissue, respec-
tively). In addition to an increased preva-
lence, a higher mycoplasma copy number 
(> 10-fold) was observed in M. hominis-
positive prostate cancer or HGPIN com-
pared with M. hominis-positive BPH tissue 
(Barykova et al., 2011). Patients with pros-
tate cancer or HGPIN also showed in-
creased seropositivity for M. hominis and 
M. hyorhinis antibodies compared with in-
dividuals suffering from BPH (Barykova et 
al., 2011; Urbanek et al., 2011). A recent 
study also reported a significantly increased 
Mycoplasma sp. infection ratio in cancerous 
tissue (35 %) compared with neighbouring 
benign tissue (13 %) in prostate biopsies 
from patients suffering adenocarcinoma of 
the prostate (Erturhan et al., 2013). In this 
study, no mycoplasmas were detected in 
prostate biopsies derived from patients suf-
fering BPH. 
A preferential colonization of the tumor 
site (82 %) compared with surrounding 
normal tissue (36 %) was also reported in 
33 patients with conventional renal cell car-
cinoma (cRCC) (Pehlivan et al., 2005). His-
tological grading of the samples showed in-
creased mycoplasma infection ratios in 
grade 3 - -4 samples compared with grade 
1 - 2 samples. Moreover, cRCC patients 
without mycoplasmas were all character-
ized by low histological grade. However, 
there was no statistical difference between 
the mycoplasma prevalence in premalignant 
(renal intratubular neoplasia; 67 %) and 
malignant (82 %) tissue. Mycoplasmas 
were also detected in normal kidney tissue 
from healthy individuals, but at a much 
lower rate (15 %). 
Pehlivan et al. (2004) reported a higher 
mycoplasma infection rate in lung tissue of 
patients suffering from small cell lung can-
cer (22 %) compared with tissue derived 
from a healthy control group (5 %). More 
recently, Apostoulou et al. (2011) found all 
assayed tissue samples that were surgically 
removed from lung cancer patients and ana-
lyzed for various prokaryotes and fungi to 
be positive for mycoplasmas. However, it 
seems that no samples derived from a con-
trol group were assayed so it cannot be ex-
cluded that this exceptionally high infection 
rate is due to external contamination of the 
samples or reagents. 
The above-mentioned studies indicate 
an increased mycoplasma colonization of 
tumor tissue in cancer patients compared 
with (i) healthy tissue in the vicinity of the 
tumor site; (ii) non-malignant diseased tis-
sue or (iii) healthy tissue derived from con-
trol patients. As suggested by Cummins and 
Tangney (2013), the preferential coloniza-
tion of cancer cells by prokaryotes may be 
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attributed to an increased nutrient availabil-
ity at the tumor site (e.g. due to necrosis) or 
bacterial chemotaxis. A possible explana-
tion may also be found in a recent study by 
Huang and colleagues (2012) who de-
scribed the role of the tumor suppressor 
protein PTEN (phosphatase and tensin 
homolog) in the cellular defense against 
bacterial infections. PTEN deficiency in 
mammalian cells conferred hyper-suscept-
ibility to Mycoplasma sp. and Mycobacte-
rium bovis infection. As various human 
cancers display mutations or deletions in 
PTEN, tumor cells could be more prone to 
infections by opportunistic pathogens such 
as mycoplasmas. However, the role and 
consequences of the presence of myco-
plasmas at the tumor site remain to be elu-
cidated and the above-mentioned studies 
have not been performed on a large cohort 
of patients. Also, apart from the study by 
Barykova et al. (2011), no mycoplasma 
quantification in tumors has been reported 
to date. Interestingly, most studies men-
tioned above report a high prevalence of M. 
hyorhinis in human tumor tissue. However, 
the route of infection and relevance of this 
mycoplasma in the human body (M. hy-
orhinis being a swine pathogen) remains to 
be investigated.   
 
Mycoplasmas alter the cytostatic potential 
of several anticancer NAs 
As mentioned above, several studies re-
ported a decreased incorporation of dThd in 
different mycoplasma-infected cell cultures 
(Jakway and Shevach, 1984; Sinigaglia and 
Talmadge, 1985; Merkenschlager et al., 
1988). This was attributed to enzymatic 
breakdown of exogenous pyrimidine nucle-
osides by mycoplasma-encoded NPs pre-
sent in the supernatant of infected tumor 
cell cultures. Therefore, radiolabeled dThd 
incorporation was suggested as an assay for 
the detection of a mycoplasma contamina-
tion in cell cultures.  
In contrast to mammalian cells and most 
prokaryotes, mycoplasmas were found to 
encode a single NP [i.e. a pyrimidine nu-
cleoside phosphorylase (PyNP)] for the ca-
tabolism of pyrimidine nucleosides (Vande 
Voorde et al., 2012). The expression of 
such PyNP in mycoplasma-infected cell 
cultures dramatically compromised the cy-
tostatic activity of various pyrimidine-based 
NAs due to phosphorolysis of the drugs. 
The biological activity of compounds such 
as 5-FdUrd, 5-trifluorothymidine (TFT) and 
other halogenated dThd analogues was de-
creased 10- to 140-fold in mycoplasma-
infected cell cultures due to PyNP-related 
conversion to less active (or inactive) nu-
cleobases. Administration of the drugs 
along with a specific TP/PyNP inhibitor or 
elimination of the mycoplasmas using anti-
biotics rescued the cytostatic potential of 
these NAs (Bronckaers et al., 2008). Also, 
Jetté and colleagues (2008) found HCT116 
colon cancer cell cultures to be 5- and 100-
fold more resistant to 5-FU and 5-FdUrd, 
respectively, when contaminated with my-
coplasmas.  
Conversely, the activity of nucleoside-
based drugs requiring phosphorolysis as an 
activation step was increased in mycoplas-
ma-infected tumor cell cultures. The cyto-
static potential of 5’-deoxy-5-fluorouridine 
(5’-DFUR), an intermediate metabolite of 
capecitabine, was increased >30-fold due to 
mycoplasma-encoded PyNP expression, ef-
ficiently converting the prodrug 5’-DFUR 
into its active metabolite 5-FU (Bronckaers, 
et al., 2008). Similarly, the non-toxic purine 
nucleoside analogue 6-MeP-dR was shown 
to severely affect mycoplasma-infected but 
not mycoplasma-free control tumor cell cul-
tures. This was attributed to mycoplasma-
encoded adenosine phosphorylase activity 
releasing the highly toxic 6-MeP from 6-
MeP-dR. Recently, the M. hyorhinis PNP 
was characterized and in contrast to its 
mammalian counterpart this enzyme also 
catalyzes the phosphorolysis of adenosine 
and different therapeutic purine nucleoside 
analogues including cladribine (2-CdA), F-
ara-A and 6-MeP-dR (Vande Voorde et al., 
2013). Depending on the properties and me-
tabolism of the nucleobase released upon 
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phosphorolysis of therapeutic NAs, a my-
coplasma infection may therefore result in a 
decreased (as was observed for 2-CdA) or 
increased (as was observed for F-ara-A and 
6-MeP-dR) cytostatic activity of the drugs. 
These biological effects can be normalized 
by the co-administration of mycoplasma-
directed antibiotics or a specific PNP inhib-
itor. 
Also, the cytostatic activity of the anti-
cancer drug gemcitabine (used for the 
treatment of pancreatic, lung, breast and 
bladder cancer) was found to be decreased 
in mycoplasma-infected tumor cell cultures 
(Vande Voorde et al., 2009) due to the ex-
pression of a mycoplasma-encoded Cyd/ 
dCyd deaminase (Vande Voorde, 2013). 
Preliminary in vivo studies confirmed a de-
creased anticancer effect of the drug in my-
coplasma-infected mammary tumors in 
mice compared with uninfected control tu-
mors (Vande Voorde, 2013).   
 
CONCLUDING REMARKS 
The presence of commensal bacteria has 
several implications in health and disease. 
Recent research revealed that an intact in-
testinal microbiome is required for the effi-
ciency of immunotherapy or chemotherapy 
with platinum, doxorubicin or cyclophos-
phamide in tumor-bearing mice (Iida et al., 
2013; Viaud et al., 2013). Several studies 
report the high and preferential colonization 
of different tumors by prokaryotes includ-
ing mycoplasmas. Such mycoplasmas, pre-
sent in the tumor microenvironment, may 
affect the efficiency of nucleoside-based 
antimetabolites. These findings argue for a 
careful consideration and possibly rational 
exploitation of the microbial target envi-
ronment when optimizing nucleoside-based 
therapy (Liekens et al., 2009). It has been 
shown before that microbiota may influence 
the metabolism of NAs (Okuda et al., 1998; 
Parker, 2009). Metabolic phenotyping of 
body fluids or tissues has been proposed to 
predict the therapeutic outcome or potential 
toxicity of drugs (defined as pharma-
cometabonomics) (Clayton et al., 2006). 
Such approach fits in the framework of pre-
cision medicine: the search for personalized 
healthcare by selection of appropriate tar-
geted therapy based on biological infor-
mation (either genetic, metabolic or physio-
logic). In this respect, the co-administration 
of a specific enzyme inhibitor or myco-
plasma-directed antibiotic together with 
therapeutic NAs may prevent selective drug 
inactivation at the target site. Alternatively, 
a rational choice of drugs when treating 
mycoplasma-infected tumors could result in 
a more pronounced therapeutic selectivity. 
This may include (i) NP-insensitive deriva-
tives of (approved) drugs (McGuigan et al., 
2011; Vande Voorde et al., 2011) or (ii) 
compounds (i.e. prodrugs) that display an 
increased biological activity after phos-
phorolysis. An extensive study quantifying 
mycoplasmas in available tumor tissues and 
relating these findings to therapeutic out-
come may reveal whether a pharmacometa-
bonomic approach of nucleoside-based the-
rapy could address inter-individual re-
sponses, improve drug efficacy and reduce 
adverse drug reactions. 
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